<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36291129</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>20</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Deficient Sarcolemma Repair in ALS: A Novel Mechanism with Therapeutic Potential.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3263</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11203263</ELocationID><Abstract><AbstractText>The plasma membrane (sarcolemma) of skeletal muscle myofibers is susceptible to injury caused by physical and chemical stresses during normal daily movement and/or under disease conditions. These acute plasma membrane disruptions are normally compensated by an intrinsic membrane resealing process involving interactions of multiple intracellular proteins including dysferlin, annexin, caveolin, and Mitsugumin 53 (MG53)/TRIM72. There is new evidence for compromised muscle sarcolemma repair mechanisms in Amyotrophic Lateral Sclerosis (ALS). Mitochondrial dysfunction in proximity to neuromuscular junctions (NMJs) increases oxidative stress, triggering MG53 aggregation and loss of its function. Compromised membrane repair further worsens sarcolemma fragility and amplifies oxidative stress in a vicious cycle. This article is to review existing literature supporting the concept that ALS is a disease of oxidative-stress induced disruption of muscle membrane repair that compromise the integrity of the NMJs and hence augmenting muscle membrane repair mechanisms could represent a viable therapeutic strategy for ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ang</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8784-4702</Identifier><AffiliationInfo><Affiliation>Department of Kinesiology, College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, TX 76019, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Jianxun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Kinesiology, College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, TX 76019, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xuejun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Kinesiology, College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, TX 76019, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Kinesiology, College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, TX 76019, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostrow</LastName><ForeName>Lyle W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19122, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jianjie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Virginia, Charlottesville, VA 22903, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jingsong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Kinesiology, College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, TX 76019, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS105621</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG071676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL138570</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG072430</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR057404</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017302">Annexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022461">Caveolins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073939">Dysferlin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017302" MajorTopicYN="N">Annexins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022461" MajorTopicYN="N">Caveolins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073939" MajorTopicYN="N">Dysferlin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012508" MajorTopicYN="Y">Sarcolemma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012038" MajorTopicYN="Y">Regeneration</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">MG53</Keyword><Keyword MajorTopicYN="N">ROS</Keyword><Keyword MajorTopicYN="N">membrane repair</Keyword><Keyword MajorTopicYN="N">sarcolemma permeability</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36291129</ArticleId><ArticleId IdType="pmc">PMC9600524</ArticleId><ArticleId IdType="doi">10.3390/cells11203263</ArticleId><ArticleId IdType="pii">cells11203263</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Vucic S., Talbot K., McDermott C.J., Hardiman O., Shefner J.M., Al-Chalabi A., Huynh W., Cudkowicz M., Talman P. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2021;17:104&#x2013;118. doi: 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., van den Berg L.H., Kiernan M.C. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;7:639&#x2013;649. doi: 10.1038/nrneurol.2011.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler J.P., Picchiarelli G., Dupuis L., Gonzalez De Aguilar J.L. The Role of Skeletal Muscle in Amyotrophic Lateral Sclerosis. Brain Pathol. 2016;26:227&#x2013;236. doi: 10.1111/bpa.12350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12350</ArticleId><ArticleId IdType="pmc">PMC8029271</ArticleId><ArticleId IdType="pubmed">26780251</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M., Swash M., Pinto S. Diaphragmatic Neurophysiology and Respiratory Markers in ALS. Front. Neurol. 2019;10:143. doi: 10.3389/fneur.2019.00143.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00143</ArticleId><ArticleId IdType="pmc">PMC6393326</ArticleId><ArticleId IdType="pubmed">30846968</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S., Murn M., Choi P.J. Respiratory Failure in Amyotrophic Lateral Sclerosis. Chest. 2019;155:401&#x2013;408. doi: 10.1016/j.chest.2018.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.06.035</ArticleId><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen Q.T., Son Y.J., Sanes J.R., Lichtman J.W. Nerve terminals form but fail to mature when postsynaptic differentiation is blocked: In vivo analysis using mammalian nerve-muscle chimeras. J. Neurosci. 2000;20:6077&#x2013;6086. doi: 10.1523/JNEUROSCI.20-16-06077.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-16-06077.2000</ArticleId><ArticleId IdType="pmc">PMC6772575</ArticleId><ArticleId IdType="pubmed">10934257</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Aucello M., Rizzuto E., Beccafico S., Mammucari C., Boncompagni S., Belia S., Wannenes F., Nicoletti C., Del Prete Z., et al. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab. 2008;8:425&#x2013;436. doi: 10.1016/j.cmet.2008.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2008.09.002</ArticleId><ArticleId IdType="pubmed">19046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M., Martin L.J. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum. Mol. Genet. 2010;19:2284&#x2013;2302. doi: 10.1093/hmg/ddq106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq106</ArticleId><ArticleId IdType="pmc">PMC2865380</ArticleId><ArticleId IdType="pubmed">20223753</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Ma C., Yi J., Wu S., Luo G., Xu X., Lin P.H., Sun J., Zhou J. Suppressed autophagy flux in skeletal muscle of an amyotrophic lateral sclerosis mouse model during disease progression. Physiol. Rep. 2015;3:e12271. doi: 10.14814/phy2.12271.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.12271</ArticleId><ArticleId IdType="pmc">PMC4387765</ArticleId><ArticleId IdType="pubmed">25602021</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo G., Yi J., Ma C., Xiao Y., Yi F., Yu T., Zhou J. Defective mitochondrial dynamics is an early event in skeletal muscle of an amyotrophic lateral sclerosis mouse model. PLoS ONE. 2013;8:e82112. doi: 10.1371/journal.pone.0082112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0082112</ArticleId><ArticleId IdType="pmc">PMC3855744</ArticleId><ArticleId IdType="pubmed">24324755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Yi J., Li X., Xiao Y., Dhakal K., Zhou J. ALS-associated mutation SOD1(G93A) leads to abnormal mitochondrial dynamics in osteocytes. Bone. 2018;106:126&#x2013;138. doi: 10.1016/j.bone.2017.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bone.2017.10.010</ArticleId><ArticleId IdType="pmc">PMC5718158</ArticleId><ArticleId IdType="pubmed">29030231</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi J., Ma C., Li Y., Weisleder N., Rios E., Ma J., Zhou J. Mitochondrial calcium uptake regulates rapid calcium transients in skeletal muscle during excitation-contraction (E-C) coupling. J. Biol. Chem. 2011;286:32436&#x2013;32443. doi: 10.1074/jbc.M110.217711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.217711</ArticleId><ArticleId IdType="pmc">PMC3173159</ArticleId><ArticleId IdType="pubmed">21795684</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Karam C., Yi J., Zhang L., Li X., Yoon D., Wang H., Dhakal K., Ramlow P., Yu T., et al. ROS-related mitochondrial dysfunction in skeletal muscle of an ALS mouse model during the disease progression. Pharm. Res. 2018;138:25&#x2013;36. doi: 10.1016/j.phrs.2018.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2018.09.008</ArticleId><ArticleId IdType="pmc">PMC6263743</ArticleId><ArticleId IdType="pubmed">30236524</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Li A., Li X., Yi J. Dysregulated mitochondrial Ca(2+) and ROS signaling in skeletal muscle of ALS mouse model. Arch. Biochem. Biophys. 2019;663:249&#x2013;258. doi: 10.1016/j.abb.2019.01.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2019.01.024</ArticleId><ArticleId IdType="pmc">PMC6506190</ArticleId><ArticleId IdType="pubmed">30682329</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Yi J., Fu R., Liu E., Siddique T., Rios E., Deng H.X. Hyperactive intracellular calcium signaling associated with localized mitochondrial defects in skeletal muscle of an animal model of amyotrophic lateral sclerosis. J. Biol. Chem. 2010;285:705&#x2013;712. doi: 10.1074/jbc.M109.041319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.041319</ArticleId><ArticleId IdType="pmc">PMC2804218</ArticleId><ArticleId IdType="pubmed">19889637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu K., Yi J., Xiao Y., Lai Y., Song P., Zheng W., Jiao H., Fan J., Wu C., Chen D., et al. Impaired bone homeostasis in amyotrophic lateral sclerosis mice with muscle atrophy. J. Biol. Chem. 2015;290:8081&#x2013;8094. doi: 10.1074/jbc.M114.603985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.603985</ArticleId><ArticleId IdType="pmc">PMC4375466</ArticleId><ArticleId IdType="pubmed">25648889</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M., Melamed E., Offen D. The "dying-back" phenomenon of motor neurons in ALS. J. Mol. Neurosci. 2011;43:470&#x2013;477. doi: 10.1007/s12031-010-9467-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9467-1</ArticleId><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp. Neurol. 2004;185:232&#x2013;240. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey D., Schneider C., Xu L., Borg J., Spooren W., Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J. Neurosci. 2000;20:2534&#x2013;2542. doi: 10.1523/JNEUROSCI.20-07-02534.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-07-02534.2000</ArticleId><ArticleId IdType="pmc">PMC6772256</ArticleId><ArticleId IdType="pubmed">10729333</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark J.A., Southam K.A., Blizzard C.A., King A.E., Dickson T.C. Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. J. Chem. Neuroanat. 2016;76:35&#x2013;47. doi: 10.1016/j.jchemneu.2016.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2016.03.003</ArticleId><ArticleId IdType="pubmed">27038603</ArticleId></ArticleIdList></Reference><Reference><Citation>Campanari M.L., Bourefis A.R., Kabashi E. Diagnostic Challenge and Neuromuscular Junction Contribution to ALS Pathogenesis. Front. Neurol. 2019;10:68. doi: 10.3389/fneur.2019.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00068</ArticleId><ArticleId IdType="pmc">PMC6372519</ArticleId><ArticleId IdType="pubmed">30787905</ArticleId></ArticleIdList></Reference><Reference><Citation>Martineau E., Di Polo A., Vande Velde C., Robitaille R. Dynamic neuromuscular remodeling precedes motor-unit loss in a mouse model of ALS. Elife. 2018;7:e41973. doi: 10.7554/eLife.41973.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.41973</ArticleId><ArticleId IdType="pmc">PMC6234026</ArticleId><ArticleId IdType="pubmed">30320556</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello V., Francolini M. Neuromuscular Junction Dismantling in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2017;18:2092. doi: 10.3390/ijms18102092.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18102092</ArticleId><ArticleId IdType="pmc">PMC5666774</ArticleId><ArticleId IdType="pubmed">28972545</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Gonzalez de Aguilar J.L., Echaniz-Laguna A., Eschbach J., Rene F., Oudart H., Halter B., Huze C., Schaeffer L., Bouillaud F., et al. Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. PLoS ONE. 2009;4:e5390. doi: 10.1371/journal.pone.0005390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005390</ArticleId><ArticleId IdType="pmc">PMC2671839</ArticleId><ArticleId IdType="pubmed">19404401</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam C., Yi J., Xiao Y., Dhakal K., Zhang L., Li X., Manno C., Xu J., Li K., Cheng H. Absence of physiological Ca 2+ transients is an initial trigger for mitochondrial dysfunction in skeletal muscle following denervation. Skelet. Muscle. 2017;7:6. doi: 10.1186/s13395-017-0123-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13395-017-0123-0</ArticleId><ArticleId IdType="pmc">PMC5387329</ArticleId><ArticleId IdType="pubmed">28395670</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrane J., Cortez C., Gan W.B., Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum. Mol. Genet. 2014;23:1413&#x2013;1424. doi: 10.1093/hmg/ddt528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt528</ArticleId><ArticleId IdType="pmc">PMC3929084</ArticleId><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S., Salvatori I., Ferri A., Valle C. Skeletal Muscle in ALS: An Unappreciated Therapeutic Opportunity? Cells. 2021;10:525. doi: 10.3390/cells10030525.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10030525</ArticleId><ArticleId IdType="pmc">PMC8000428</ArticleId><ArticleId IdType="pubmed">33801336</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper S.T., McNeil P.L. Membrane Repair: Mechanisms and Pathophysiology. Physiol. Rev. 2015;95:1205&#x2013;1240. doi: 10.1152/physrev.00037.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00037.2014</ArticleId><ArticleId IdType="pmc">PMC4600952</ArticleId><ArticleId IdType="pubmed">26336031</ArticleId></ArticleIdList></Reference><Reference><Citation>Han R., Campbell K.P. Dysferlin and muscle membrane repair. Curr. Opin. Cell Biol. 2007;19:409&#x2013;416. doi: 10.1016/j.ceb.2007.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceb.2007.07.001</ArticleId><ArticleId IdType="pmc">PMC2144911</ArticleId><ArticleId IdType="pubmed">17662592</ArticleId></ArticleIdList></Reference><Reference><Citation>Demonbreun A.R., McNally E.M. Plasma Membrane Repair in Health and Disease. Curr. Top. Membr. 2016;77:67&#x2013;96. doi: 10.1016/bs.ctm.2015.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ctm.2015.10.006</ArticleId><ArticleId IdType="pmc">PMC4827257</ArticleId><ArticleId IdType="pubmed">26781830</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzerro E., Bonetto A., Minetti C. Caveolinopathies: Translational implications of caveolin-3 in skeletal and cardiac muscle disorders. Handb. Clin. Neurol. 2011;101:135&#x2013;142. doi: 10.1016/B978-0-08-045031-5.00010-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-08-045031-5.00010-4</ArticleId><ArticleId IdType="pubmed">21496630</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Wang L., Yue H., Whitson B.A., Haggard E., Xu X., Ma J. MG53, A Tissue Repair Protein with Broad Applications in Regenerative Medicine. Cells. 2021;10:122. doi: 10.3390/cells10010122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010122</ArticleId><ArticleId IdType="pmc">PMC7827922</ArticleId><ArticleId IdType="pubmed">33440658</ArticleId></ArticleIdList></Reference><Reference><Citation>Neel B.A., Lin Y., Pessin J.E. Skeletal muscle autophagy: A new metabolic regulator. Trends Endocrinol. Metab. TEM. 2013;24:635&#x2013;643. doi: 10.1016/j.tem.2013.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2013.09.004</ArticleId><ArticleId IdType="pmc">PMC3849822</ArticleId><ArticleId IdType="pubmed">24182456</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen S., Nielsen J., Hansen C.N., Nielsen L.B., Wibrand F., Stride N., Schroder H.D., Boushel R., Helge J.W., Dela F., et al. Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. J. Physiol. 2012;590:3349&#x2013;3360. doi: 10.1113/jphysiol.2012.230185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2012.230185</ArticleId><ArticleId IdType="pmc">PMC3459047</ArticleId><ArticleId IdType="pubmed">22586215</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.F., Shaw P.J., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Carri M.T., D&#x2019;Ambrosi N., Cozzolino M. Pathways to mitochondrial dysfunction in ALS pathogenesis. Biochem. Biophys. Res. Commun. 2017;483:1187&#x2013;1193. doi: 10.1016/j.bbrc.2016.07.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.07.055</ArticleId><ArticleId IdType="pubmed">27416757</ArticleId></ArticleIdList></Reference><Reference><Citation>Echaniz-Laguna A., Zoll J., Ponsot E., N&#x2019;Guessan B., Tranchant C., Loeffler J.P., Lampert E. Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: A temporal study in man. Exp. Neurol. 2006;198:25&#x2013;30. doi: 10.1016/j.expneurol.2005.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.07.020</ArticleId><ArticleId IdType="pubmed">16126198</ArticleId></ArticleIdList></Reference><Reference><Citation>Napoli L., Crugnola V., Lamperti C., Silani V., Di Mauro S., Bresolin N., Moggio M. Ultrastructural mitochondrial abnormalities in patients with sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2011;68:1612&#x2013;1613. doi: 10.1001/archneur.68.12.1612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.68.12.1612</ArticleId><ArticleId IdType="pubmed">22159065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S., Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2007;66:10&#x2013;16. doi: 10.1097/nen.0b013e31802c396b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31802c396b</ArticleId><ArticleId IdType="pubmed">17204932</ArticleId></ArticleIdList></Reference><Reference><Citation>Siciliano G., Pastorini E., Pasquali L., Manca M.L., Iudice A., Murri L. Impaired oxidative metabolism in exercising muscle from ALS patients. J. Neurol. Sci. 2001;191:61&#x2013;65. doi: 10.1016/S0022-510X(01)00620-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00620-7</ArticleId><ArticleId IdType="pubmed">11676993</ArticleId></ArticleIdList></Reference><Reference><Citation>Soraru G., Vergani L., Fedrizzi L., D&#x2019;Ascenzo C., Polo A., Bernazzi B., Angelini C. Activities of mitochondrial complexes correlate with nNOS amount in muscle from ALS patients. Neuropathol. Appl. Neurobiol. 2007;33:204&#x2013;211. doi: 10.1111/j.1365-2990.2006.00791.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2006.00791.x</ArticleId><ArticleId IdType="pubmed">17359361</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann F.R., Manfredi G., Mawrin C., Beal M.F., Schon E.A. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J. Neurochem. 2002;80:616&#x2013;625. doi: 10.1046/j.0022-3042.2001.00731.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0022-3042.2001.00731.x</ArticleId><ArticleId IdType="pubmed">11841569</ArticleId></ArticleIdList></Reference><Reference><Citation>Carri M.T., Valle C., Bozzo F., Cozzolino M. Oxidative stress and mitochondrial damage: Importance in non-SOD1 ALS. Front. Cell Neurosci. 2015;9:41. doi: 10.3389/fncel.2015.00041.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00041</ArticleId><ArticleId IdType="pmc">PMC4330888</ArticleId><ArticleId IdType="pubmed">25741238</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E., Factor-Litvak P., Santella R.M., Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol. Med. 2013;65:509&#x2013;527. doi: 10.1016/j.freeradbiomed.2013.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.06.029</ArticleId><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., Yong V.W. Oxidized phospholipids as novel mediators of neurodegeneration. Trends Neurosci. 2022;45:419&#x2013;429. doi: 10.1016/j.tins.2022.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2022.03.002</ArticleId><ArticleId IdType="pubmed">35393134</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Carri M.T., Cozzolino M. SOD1 and mitochondria in ALS: A dangerous liaison. J. Bioenerg Biomembr. 2011;43:593&#x2013;599. doi: 10.1007/s10863-011-9394-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10863-011-9394-z</ArticleId><ArticleId IdType="pubmed">22081209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanova M.I., Sievers S.A., Guenther E.L., Johnson L.M., Winkler D.D., Galaleldeen A., Sawaya M.R., Hart P.J., Eisenberg D.S. Aggregation-triggering segments of SOD1 fibril formation support a common pathway for familial and sporadic ALS. Proc. Natl. Acad. Sci. USA. 2014;111:197&#x2013;201. doi: 10.1073/pnas.1320786110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1320786110</ArticleId><ArticleId IdType="pmc">PMC3890817</ArticleId><ArticleId IdType="pubmed">24344300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Bendotti C., Blaugrund E., Chio A., Greensmith L., Loeffler J.P., Mead R., Niessen H.G., Petri S., Pradat P.F., et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph. Lateral Scler. 2010;11:38&#x2013;45. doi: 10.3109/17482960903545334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick P., Joyce P.I., Fisher E.M., Greensmith L. Rodent models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta. 2013;1832:1421&#x2013;1436. doi: 10.1016/j.bbadis.2013.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2013.03.012</ArticleId><ArticleId IdType="pubmed">23524377</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller F.L., Song W., Jang Y.C., Liu Y., Sabia M., Richardson A., Van Remmen H. Denervation-induced skeletal muscle atrophy is associated with increased mitochondrial ROS production. Am. J. Physiol. Regul Integr. Comp. Physiol. 2007;293:R1159&#x2013;R1168. doi: 10.1152/ajpregu.00767.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00767.2006</ArticleId><ArticleId IdType="pubmed">17584954</ArticleId></ArticleIdList></Reference><Reference><Citation>Halter B., Gonzalez de Aguilar J.L., Rene F., Petri S., Fricker B., Echaniz-Laguna A., Dupuis L., Larmet Y., Loeffler J.P. Oxidative stress in skeletal muscle stimulates early expression of Rad in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol. Med. 2010;48:915&#x2013;923. doi: 10.1016/j.freeradbiomed.2010.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2010.01.014</ArticleId><ArticleId IdType="pubmed">20079427</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S.M., El Oussini H., Scekic-Zahirovic J., Vibbert J., Cottee P., Prasain J.K., Bellen H.J., Dupuis L., Miller M.A. VAPB/ALS8 MSP ligands regulate striated muscle energy metabolism critical for adult survival in caenorhabditis elegans. PLoS Genet. 2013;9:e1003738. doi: 10.1371/journal.pgen.1003738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1003738</ArticleId><ArticleId IdType="pmc">PMC3764199</ArticleId><ArticleId IdType="pubmed">24039594</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings N.R., Puttaparthi K., Dowling K.J., Luther C.M., Burns D.K., Davis K., Elliott J.L. TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis. PLoS ONE. 2013;8:e71793. doi: 10.1371/journal.pone.0071793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0071793</ArticleId><ArticleId IdType="pmc">PMC3742534</ArticleId><ArticleId IdType="pubmed">23967244</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitanio D., Vasso M., Ratti A., Grignaschi G., Volta M., Moriggi M., Daleno C., Bendotti C., Silani V., Gelfi C. Molecular signatures of amyotrophic lateral sclerosis disease progression in hind and forelimb muscles of an SOD1(G93A) mouse model. Antioxid Redox Signal. 2012;17:1333&#x2013;1350. doi: 10.1089/ars.2012.4524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.4524</ArticleId><ArticleId IdType="pmc">PMC3437050</ArticleId><ArticleId IdType="pubmed">22563797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Fang H., Groom L., Cheng A., Zhang W., Liu J., Wang X., Li K., Han P., Zheng M., et al. Superoxide flashes in single mitochondria. Cell. 2008;134:279&#x2013;290. doi: 10.1016/j.cell.2008.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.06.017</ArticleId><ArticleId IdType="pmc">PMC2547996</ArticleId><ArticleId IdType="pubmed">18662543</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang H., Chen M., Ding Y., Shang W., Xu J., Zhang X., Zhang W., Li K., Xiao Y., Gao F., et al. Imaging superoxide flash and metabolism-coupled mitochondrial permeability transition in living animals. Cell Res. 2011;21:1295&#x2013;1304. doi: 10.1038/cr.2011.81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2011.81</ArticleId><ArticleId IdType="pmc">PMC3193463</ArticleId><ArticleId IdType="pubmed">21556035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L., Salahura G., Boncompagni S., Kasischke K.A., Protasi F., Sheu S.S., Dirksen R.T. Mitochondrial superoxide flashes: Metabolic biomarkers of skeletal muscle activity and disease. FASEB J. 2011;25:3068&#x2013;3078. doi: 10.1096/fj.11-187252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.11-187252</ArticleId><ArticleId IdType="pmc">PMC3157685</ArticleId><ArticleId IdType="pubmed">21646399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y., Fang H., Shang W., Xiao Y., Sun T., Hou N., Pan L., Sun X., Ma Q., Zhou J., et al. Mitoflash altered by metabolic stress in insulin-resistant skeletal muscle. J. Mol. Med. (Berl) 2015;93:1119&#x2013;1130. doi: 10.1007/s00109-015-1278-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-015-1278-y</ArticleId><ArticleId IdType="pmc">PMC4589561</ArticleId><ArticleId IdType="pubmed">25908643</ArticleId></ArticleIdList></Reference><Reference><Citation>Batandier C., Leverve X., Fontaine E. Opening of the mitochondrial permeability transition pore induces reactive oxygen species production at the level of the respiratory chain complex I. J. Biol. Chem. 2004;279:17197&#x2013;17204. doi: 10.1074/jbc.M310329200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M310329200</ArticleId><ArticleId IdType="pubmed">14963044</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookes P.S., Yoon Y., Robotham J.L., Anders M.W., Sheu S.S. Calcium, ATP, and ROS: A mitochondrial love-hate triangle. Am. J. Physiol. Cell Physiol. 2004;287:C817&#x2013;C833. doi: 10.1152/ajpcell.00139.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00139.2004</ArticleId><ArticleId IdType="pubmed">15355853</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A., Yi J., Li X., Zhou J. Physiological Ca2+ Transients Versus Pathological Steady-State Ca2+ Elevation, Who Flips the ROS Coin in Skeletal Muscle Mitochondria. Front. Physiol. 2020;11:595800. doi: 10.3389/fphys.2020.595800.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.595800</ArticleId><ArticleId IdType="pmc">PMC7642813</ArticleId><ArticleId IdType="pubmed">33192612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott M., Robertson J.D., Gogvadze V., Zhivotovsky B., Orrenius S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc. Natl. Acad. Sci. USA. 2002;99:1259&#x2013;1263. doi: 10.1073/pnas.241655498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.241655498</ArticleId><ArticleId IdType="pmc">PMC122177</ArticleId><ArticleId IdType="pubmed">11818574</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrens J.F., Alexandre A., Lehninger A.L. Ubisemiquinone is the electron donor for superoxide formation by complex III of heart mitochondria. Arch. Biochem. Biophys. 1985;237:408&#x2013;414. doi: 10.1016/0003-9861(85)90293-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-9861(85)90293-0</ArticleId><ArticleId IdType="pubmed">2983613</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller F., Crofts A.R., Kramer D.M. Multiple Q-cycle bypass reactions at the Qo site of the cytochrome bc 1 complex. Biochemistry. 2002;41:7866&#x2013;7874. doi: 10.1021/bi025581e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi025581e</ArticleId><ArticleId IdType="pubmed">12069575</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller F.L., Roberts A.G., Bowman M.K., Kramer D.M. Architecture of the Qo site of the cytochrome bc 1 complex probed by superoxide production. Biochemistry. 2003;42:6493&#x2013;6499. doi: 10.1021/bi0342160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0342160</ArticleId><ArticleId IdType="pubmed">12767232</ArticleId></ArticleIdList></Reference><Reference><Citation>Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., Brunskill E.W., Sayen M.R., Gottlieb R.A., Dorn G.W., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658&#x2013;662. doi: 10.1038/nature03434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03434</ArticleId><ArticleId IdType="pubmed">15800627</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso E., Fante L., Fowlkes J., Petronilli V., Forte M.A., Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin, D.J. Biol. Chem. 2005;280:18558&#x2013;18561. doi: 10.1074/jbc.C500089200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C500089200</ArticleId><ArticleId IdType="pubmed">15792954</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., Inohara H., Kubo T., Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434:652&#x2013;658. doi: 10.1038/nature03317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03317</ArticleId><ArticleId IdType="pubmed">15800626</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A., Li X., Yi J., Ma J., Zhou J. Butyrate Feeding Reverses CypD-Related Mitoflash Phenotypes in Mouse Myofibers. Int. J. Mol. Sci. 2021;22:7412. doi: 10.3390/ijms22147412.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22147412</ArticleId><ArticleId IdType="pmc">PMC8304904</ArticleId><ArticleId IdType="pubmed">34299032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L., Dirksen R.T. Mitochondrial superoxide flashes: From discovery to new controversies. J. Gen. Physiol. 2012;139:425&#x2013;434. doi: 10.1085/jgp.201210790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1085/jgp.201210790</ArticleId><ArticleId IdType="pmc">PMC3362526</ArticleId><ArticleId IdType="pubmed">22641637</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonora M., Giorgi C., Pinton P. Molecular mechanisms and consequences of mitochondrial permeability transition. Nat. Rev. Mol. Cell Biol. 2022;23:266&#x2013;285. doi: 10.1038/s41580-021-00433-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00433-y</ArticleId><ArticleId IdType="pubmed">34880425</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamer P.W., McGeachie J.M., Davies M.J., Grounds M.D. Evans Blue Dye as an in vivo marker of myofibre damage: Optimising parameters for detecting initial myofibre membrane permeability. J. Anat. 2002;200:69&#x2013;79. doi: 10.1046/j.0021-8782.2001.00008.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0021-8782.2001.00008.x</ArticleId><ArticleId IdType="pmc">PMC1570883</ArticleId><ArticleId IdType="pubmed">11837252</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooddell C.I., Radley-Crabb H.G., Griffin J.B., Zhang G. Myofiber Damage Evaluation by Evans Blue Dye Injection. Curr. Protoc. Mouse Biol. 2011;1:463&#x2013;488. doi: 10.1002/9780470942390.mo110141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470942390.mo110141</ArticleId><ArticleId IdType="pubmed">26069001</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda R., Nishikawa A., Tanaka H. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: Evidence of apoptosis in dystrophin-deficient muscle. J. Biochem. 1995;118:959&#x2013;964. doi: 10.1093/jb/118.5.959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jb/118.5.959</ArticleId><ArticleId IdType="pubmed">8749313</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C., Masumiya H., Weisleder N., Matsuda N., Nishi M., Hwang M., Ko J.K., Lin P., Thornton A., Zhao X., et al. MG53 nucleates assembly of cell membrane repair machinery. Nat. Cell Biol. 2009;11:56&#x2013;64. doi: 10.1038/ncb1812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1812</ArticleId><ArticleId IdType="pmc">PMC2990407</ArticleId><ArticleId IdType="pubmed">19043407</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi J., Li A., Li X., Park K., Zhou X., Yi F., Xiao Y., Yoon D., Tan T., Ostrow L.W., et al. MG53 Preserves Neuromuscular Junction Integrity and Alleviates ALS Disease Progression. Antioxidants. 2021;10:1522. doi: 10.3390/antiox10101522.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10101522</ArticleId><ArticleId IdType="pmc">PMC8532806</ArticleId><ArticleId IdType="pubmed">34679657</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil P.L., Miyake K., Vogel S.S. The endomembrane requirement for cell surface repair. Proc. Natl. Acad. Sci. USA. 2003;100:4592&#x2013;4597. doi: 10.1073/pnas.0736739100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0736739100</ArticleId><ArticleId IdType="pmc">PMC153600</ArticleId><ArticleId IdType="pubmed">12672953</ArticleId></ArticleIdList></Reference><Reference><Citation>Fucile S. Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium. 2004;35:1&#x2013;8. doi: 10.1016/j.ceca.2003.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2003.08.006</ArticleId><ArticleId IdType="pubmed">14670366</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., Molinaro M., Rosenthal N., Musaro A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005;168:193&#x2013;199. doi: 10.1083/jcb.200407021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200407021</ArticleId><ArticleId IdType="pmc">PMC2171577</ArticleId><ArticleId IdType="pubmed">15657392</ArticleId></ArticleIdList></Reference><Reference><Citation>Cejas P., Casado E., Belda-Iniesta C., De Castro J., Espinosa E., Redondo A., Sereno M., Garcia-Cabezas M.A., Vara J.A., Dominguez-Caceres A., et al. Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain) Cancer Causes Control. 2004;15:707&#x2013;719. doi: 10.1023/B:CACO.0000036189.61607.52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:CACO.0000036189.61607.52</ArticleId><ArticleId IdType="pubmed">15280629</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozato K., Shin D.M., Chang T.H., Morse H.C. TRIM family proteins and their emerging roles in innate immunity. Nat. Rev. Immunol. 2008;8:849&#x2013;860. doi: 10.1038/nri2413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2413</ArticleId><ArticleId IdType="pmc">PMC3433745</ArticleId><ArticleId IdType="pubmed">18836477</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisleder N., Takeshima H., Ma J. Immuno-proteomic approach to excitation&#x2013;contraction coupling in skeletal and cardiac muscle: Molecular insights revealed by the mitsugumins. Cell Calcium. 2008;43:1&#x2013;8. doi: 10.1016/j.ceca.2007.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2007.10.006</ArticleId><ArticleId IdType="pmc">PMC3059838</ArticleId><ArticleId IdType="pubmed">18061662</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C., Weisleder N., Ko J.K., Komazaki S., Sunada Y., Nishi M., Takeshima H., Ma J. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J. Biol. Chem. 2009;284:15894&#x2013;15902. doi: 10.1074/jbc.M109.009589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.009589</ArticleId><ArticleId IdType="pmc">PMC2708885</ArticleId><ArticleId IdType="pubmed">19380584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P., Zhu H., Cai C., Wang X., Cao C., Xiao R., Pan Z., Weisleder N., Takeshima H., Ma J. Nonmuscle myosin IIA facilitates vesicle trafficking for MG53-mediated. cell membrane repair. FASEB J. 2012;26:1875&#x2013;1883. doi: 10.1096/fj.11-188599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.11-188599</ArticleId><ArticleId IdType="pmc">PMC3336789</ArticleId><ArticleId IdType="pubmed">22253476</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H., Lin P., De G., Choi K.H., Takeshima H., Weisleder N., Ma J. Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair. J. Biol. Chem. 2011;286:12820&#x2013;12824. doi: 10.1074/jbc.C111.221440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C111.221440</ArticleId><ArticleId IdType="pmc">PMC3075629</ArticleId><ArticleId IdType="pubmed">21343302</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C., Masumiya H., Weisleder N., Pan Z., Nishi M., Komazaki S., Takeshima H., Ma J. MG53 regulates membrane budding and exocytosis in muscle cells. J. Biol. Chem. 2009;284:3314&#x2013;3322. doi: 10.1074/jbc.M808866200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808866200</ArticleId><ArticleId IdType="pmc">PMC2631961</ArticleId><ArticleId IdType="pubmed">19029292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao C.M., Zhang Y., Weisleder N., Ferrante C., Wang X., Lv F., Zhang Y., Song R., Hwang M., Jin L., et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation. 2010;121:2565&#x2013;2574. doi: 10.1161/CIRCULATIONAHA.110.954628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.954628</ArticleId><ArticleId IdType="pubmed">20516375</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian Z., Wang Q., Zhou X., Tan T., Park K.H., Kramer H.F., McDougal A., Laping N.J., Kumar S., Adesanya T.M.A., et al. Sustained elevation of MG53 in the bloodstream increases tissue regenerative capacity without compromising metabolic function. Nat. Commun. 2019;10:4659. doi: 10.1038/s41467-019-12483-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12483-0</ArticleId><ArticleId IdType="pmc">PMC6789113</ArticleId><ArticleId IdType="pubmed">31604915</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M. Effects of Strength Training in Amyotrophic Lateral Sclerosis: How Much Do We Know? Muscle Nerve. 2019;59:6&#x2013;7. doi: 10.1002/mus.26347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26347</ArticleId><ArticleId IdType="pubmed">30230558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsitkanou S., Della Gatta P., Foletta V., Russell A. The Role of Exercise as a Non-pharmacological Therapeutic Approach for Amyotrophic Lateral Sclerosis: Beneficial or Detrimental? Front. Neurol. 2019;10:783. doi: 10.3389/fneur.2019.00783.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00783</ArticleId><ArticleId IdType="pmc">PMC6652799</ArticleId><ArticleId IdType="pubmed">31379732</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A., Peter R., Dorst J., Kassubek J., Rothenbacher D., Nagel G., Ludolph A.C., Group A.R.S.S. Life Course of Physical Activity and Risk and Prognosis of Amyotrophic Lateral Sclerosis in a German ALS Registry. Neurology. 2021;97:e1955&#x2013;e1963. doi: 10.1212/WNL.0000000000012829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012829</ArticleId><ArticleId IdType="pubmed">34670816</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian T.H., Glascow N., Barry A.D.F., Moll T., Harvey C., Klimentidis Y.C., Newell M., Zhang S., Snyder M.P., Cooper-Knock J. Physical exercise is a risk factor for amyotrophic lateral sclerosis: Convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes. EBioMedicine. 2021;68:103397. doi: 10.1016/j.ebiom.2021.103397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103397</ArticleId><ArticleId IdType="pmc">PMC8170114</ArticleId><ArticleId IdType="pubmed">34051439</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond J., Mehta P., Larson T., Factor-Litvak P., Davis B., Horton K. History of vigorous leisure-time physical activity and early onset amyotrophic lateral sclerosis (ALS), data from the national ALS registry: 2010&#x2013;2018. Amyotroph. Lateral Scler. Front. Degener. 2021;22:535&#x2013;544. doi: 10.1080/21678421.2021.1910308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1910308</ArticleId><ArticleId IdType="pmc">PMC8559906</ArticleId><ArticleId IdType="pubmed">33896281</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood C.A., Westgate K., Gunstone S., Brage S., Wareham N.J., McDermott C.J., Shaw P.J. Long-term physical activity: An exogenous risk factor for sporadic amyotrophic lateral sclerosis? Amyotroph. Lateral Scler. Front. Degener. 2016;17:377&#x2013;384. doi: 10.3109/21678421.2016.1154575.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1154575</ArticleId><ArticleId IdType="pmc">PMC4950417</ArticleId><ArticleId IdType="pubmed">26998882</ArticleId></ArticleIdList></Reference><Reference><Citation>Di P.W.C., Di P.S.G.C. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): A multicentre, open-label, randomised controlled trial. Lancet Neurol. 2015;14:883&#x2013;892. doi: 10.1016/S1474-4422(15)00152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00152-0</ArticleId><ArticleId IdType="pubmed">26234554</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Bermejo J., Morelot-Panzini C., Tanguy M.L., Meininger V., Pradat P.F., Lenglet T., Bruneteau G., Forestier N.L., Couratier P., Guy N., et al. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): A randomised controlled triple-blind trial. Lancet Neurol. 2016;15:1217&#x2013;1227. doi: 10.1016/S1474-4422(16)30233-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30233-2</ArticleId><ArticleId IdType="pubmed">27751553</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott C.J., Bradburn M.J., Maguire C., Cooper C.L., Baird W.O., Baxter S.K., Cohen J., Cantrill H., Dixon S., Ackroyd R., et al. DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial. Health Technol. Assess. 2016;20:1&#x2013;186. doi: 10.3310/hta20450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/hta20450</ArticleId><ArticleId IdType="pmc">PMC4939419</ArticleId><ArticleId IdType="pubmed">27353839</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Lewis R.A. Diaphragm pacing in patients with amyotrophic lateral sclerosis. Lancet Neurol. 2016;15:542. doi: 10.1016/S1474-4422(16)30012-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30012-6</ArticleId><ArticleId IdType="pubmed">27302114</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood H. Motor neuron disease: Diaphragm pacing is associated with reduced survival in ALS patients with respiratory insufficiency. Nat. Rev. Neurol. 2015;11:484. doi: 10.1038/nrneurol.2015.149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.149</ArticleId><ArticleId IdType="pubmed">26281964</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonka S., Holtmann B., Sendtner M., Metzger F. Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease. Exp. Neurol. 2011;232:261&#x2013;269. doi: 10.1016/j.expneurol.2011.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.09.015</ArticleId><ArticleId IdType="pubmed">21963648</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster R., Didier E., Harris P., Siegel N., Stadler J., Tilbury L., Smith D. PEGylated proteins: Evaluation of their safety in the absence of definitive metabolism studies. Drug Metab. Dispos. 2007;35:9&#x2013;16. doi: 10.1124/dmd.106.012419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.106.012419</ArticleId><ArticleId IdType="pubmed">17020954</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisleder N., Takizawa N., Lin P., Wang X., Cao C., Zhang Y., Tan T., Ferrante C., Zhu H., Chen P.J., et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci. Transl. Med. 2012;4:139ra185. doi: 10.1126/scitranslmed.3003921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003921</ArticleId><ArticleId IdType="pmc">PMC3777623</ArticleId><ArticleId IdType="pubmed">22723464</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H., Hou J., Roe J.L., Park K.H., Tan T., Zheng Y., Li L., Zhang C., Liu J., Liu Z., et al. Amelioration of ischemia-reperfusion-induced muscle injury by the recombinant human MG53 protein. Muscle Nerve. 2015;52:852&#x2013;858. doi: 10.1002/mus.24619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24619</ArticleId><ArticleId IdType="pmc">PMC4545465</ArticleId><ArticleId IdType="pubmed">25703692</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H., Liu J., Bian Z., Cui Y., Zhou X., Zhou X., Zhang B., Adesanya T.M., Yi F., Park K.H., et al. Effect of metabolic syndrome on mitsugumin 53 expression and function. PLoS ONE. 2015;10:e0124128. doi: 10.1371/journal.pone.0124128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0124128</ArticleId><ArticleId IdType="pmc">PMC4423930</ArticleId><ArticleId IdType="pubmed">25950605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Bian Z., Jiang Q., Wang X., Zhou X., Park K.H., Hsueh W., Whitson B.A., Haggard E., Li H., et al. MG53 does not manifest the development of diabetes in db/db mice. Diabetes. 2020;69:1052&#x2013;1064. doi: 10.2337/db19-0807.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db19-0807</ArticleId><ArticleId IdType="pmc">PMC7171965</ArticleId><ArticleId IdType="pubmed">32139593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Li X., Ong H., Tan T., Park K.H., Bian Z., Zou X., Haggard E., Janssen P.M., Merritt R.E., et al. MG53 suppresses NF-kappaB activation to mitigate age-related heart failure. JCI Insight. 2021;6:e148375. doi: 10.1172/jci.insight.148375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.148375</ArticleId><ArticleId IdType="pmc">PMC8492351</ArticleId><ArticleId IdType="pubmed">34292883</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y., Chen K., Lin P., Lieber G., Nishi M., Yan R., Wang Z., Yao Y., Li Y., Whitson B.A., et al. Treatment of acute lung injury by targeting MG53-mediated cell membrane repair. Nat. Commun. 2014;5:4387. doi: 10.1038/ncomms5387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5387</ArticleId><ArticleId IdType="pmc">PMC4109002</ArticleId><ArticleId IdType="pubmed">25034454</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Zhu H., Zheng Y., Xu Z., Li L., Tan T., Park K.H., Hou J., Zhang C., Li D., et al. Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury. J. Mol. Cell Cardiol. 2015;80:10&#x2013;19. doi: 10.1016/j.yjmcc.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2014.12.010</ArticleId><ArticleId IdType="pmc">PMC4512204</ArticleId><ArticleId IdType="pubmed">25533937</ArticleId></ArticleIdList></Reference><Reference><Citation>Duann P., Li H., Lin P., Tan T., Wang Z., Chen K., Zhou X., Gumpper K., Zhu H., Ludwig T., et al. MG53-mediated cell membrane repair protects against acute kidney injury. Sci. Transl. Med. 2015;7:279ra236. doi: 10.1126/scitranslmed.3010755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3010755</ArticleId><ArticleId IdType="pmc">PMC4524523</ArticleId><ArticleId IdType="pubmed">25787762</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y., Zhang B., Zhu H., Li H., Han Y., Chen K., Wang Z., Zeng J., Liu Y., Wang X., et al. MG53 permeates through blood-brain barrier to protect ischemic brain injury. Oncotarget. 2016;7:22474&#x2013;22485. doi: 10.18632/oncotarget.7965.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.7965</ArticleId><ArticleId IdType="pmc">PMC5008374</ArticleId><ArticleId IdType="pubmed">26967557</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>